Entrada Therapeutics (TRDA) Treasury Shares (2020 - 2026)

Entrada Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Treasury Shares rose 3.35% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 3.35% increase from a year earlier, with the FY2025 full-year figure at $438500.0, down 77.72% from the prior year.
• Treasury Shares improved to $2.8 million in Q1 2026 per TRDA's latest filing, from $438500.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $2.8 million in Q1 2026 and bottomed at $438500.0 in Q3 2024.
• The 5-year median for Treasury Shares is $1.2 million (2023), against an average of $1.3 million.
• Across the five-year window, Treasury Shares sank 99.68% in 2022 and soared 198.8% in 2024, its largest moves.
• Year by year, Treasury Shares stood at $463964.0 in 2022, then surged by 173.4% to $1.3 million in 2023, then soared by 55.18% to $2.0 million in 2024, then tumbled by 77.72% to $438500.0 in 2025, then surged by 535.59% to $2.8 million in 2026.
• Per Business Quant, the three latest TRDA Treasury Shares figures stand at $2.8 million (Q1 2026), $438500.0 (Q4 2025), and $438500.0 (Q3 2025).